Robert W. Frenck
YOU?
Author Swipe
View article: Recommendations for Prevention and Control of Influenza in Children, 2025–2026: Technical Report
Recommendations for Prevention and Control of Influenza in Children, 2025–2026: Technical Report Open
This technical report accompanies the recommendations of the American Academy of Pediatrics for the routine use of influenza vaccine and antiviral medications in the prevention and treatment of influenza in children during the 2025–2026 in…
View article: Medical vs Nonmedical Immunization Exemptions for Child Care and School Attendance: Policy Statement
Medical vs Nonmedical Immunization Exemptions for Child Care and School Attendance: Policy Statement Open
Routine childhood immunizations against infectious diseases are an integral part of our public health infrastructure. They provide direct protection to the immunized individual and indirect protection to children and adults unable to be im…
View article: Recommendations for Prevention and Control of Influenza in Children, 2025–2026: Policy Statement
Recommendations for Prevention and Control of Influenza in Children, 2025–2026: Policy Statement Open
This statement updates the recommendations of the American Academy of Pediatrics (AAP) for the use of influenza vaccines and antiviral medications in the prevention and treatment of influenza in children during the 2025–2026 influenza seas…
View article: A multifunctional anti-O-Antigen human monoclonal antibody protects against <i>Shigella sonnei</i> infection in vivo
A multifunctional anti-O-Antigen human monoclonal antibody protects against <i>Shigella sonnei</i> infection in vivo Open
Shigellosis is a global public health challenge that mostly affects low- and middle-income countries and causes considerable morbidity and mortality among children under 5 y of age. Multi- and extensively drug-resistant Shigella sonnei str…
View article: Protein-specific immune response elicited by the <i>Shigella sonnei</i> 1790GAHB GMMA-based candidate vaccine in adults with varying exposure to <i>Shigella</i>
Protein-specific immune response elicited by the <i>Shigella sonnei</i> 1790GAHB GMMA-based candidate vaccine in adults with varying exposure to <i>Shigella</i> Open
Shigella is a leading cause of diarrheal morbidity and mortality in young children from low- and middle-income countries. Here, we aimed to verify the ability of the generalized modules for membrane antigens (GMMA)-based Shigella sonnei ca…
View article: Dynamics of the gut microbiome in subjects challenged with <i>Shigella sonnei</i> 53G in a controlled human infection model
Dynamics of the gut microbiome in subjects challenged with <i>Shigella sonnei</i> 53G in a controlled human infection model Open
Shigella is a significant cause of diarrhea, predominantly affecting children in low- and middle-income countries, as well as international travelers. Not all individuals exposed to Shigella or other enteropathogens have symptomatic respon…
View article: COVID-19 Vaccination in Patients with Inborn Errors of Immunity Reduces Hospitalization and Critical Care Needs Related to COVID-19: a USIDNET Report
COVID-19 Vaccination in Patients with Inborn Errors of Immunity Reduces Hospitalization and Critical Care Needs Related to COVID-19: a USIDNET Report Open
View article: COVID-19 Vaccination in Patients with Inborn Errors of Immunity Reduces Hospitalization and Critical Care Needs Related to COVID-19: a USIDNET Report
COVID-19 Vaccination in Patients with Inborn Errors of Immunity Reduces Hospitalization and Critical Care Needs Related to COVID-19: a USIDNET Report Open
Background The CDC and ACIP recommend COVID-19 vaccination for patients with inborn errors of immunity (IEI). Not much is known about vaccine safety in IEI, and whether vaccination attenuates infection severity in IEI. Objective To estimat…
View article: Putative correlates of protection against shigellosis assessing immunomarkers across responses to S. sonnei investigational vaccine
Putative correlates of protection against shigellosis assessing immunomarkers across responses to S. sonnei investigational vaccine Open
Shigella spp. are a leading bacterial cause of diarrhea. No widely licensed vaccines are available and there is no generally accepted correlate of protection. We tested a S. sonnei Generalized Modules for Membrane Antigen (GMMA)-based vacc…
View article: B memory cell responses to LPS, IVP and IpaB antigen after oral vaccination with Shigella sonnei vaccine candidates WRSs2 and WRSs3
B memory cell responses to LPS, IVP and IpaB antigen after oral vaccination with Shigella sonnei vaccine candidates WRSs2 and WRSs3 Open
B memory (B M ) cell responses were evaluated using peripheral blood mononuclear cells that were collected and cryopreserved during a Phase 1 trial of two live Shigella sonnei vaccine candidates WRSs2 and WRSs3. An ELISpot assay was used t…
View article: Safety and Immunogenicity of a Nipah Virus Vaccine (Hev-Sg-V) in Adults: A Single-Centre, Randomised, Observer-Blind, Placebo-Controlled, Phase 1 Study
Safety and Immunogenicity of a Nipah Virus Vaccine (Hev-Sg-V) in Adults: A Single-Centre, Randomised, Observer-Blind, Placebo-Controlled, Phase 1 Study Open
View article: COVID-19 Vaccines in Children
COVID-19 Vaccines in Children Open
The COVID-19 pandemic has left an indelible mark on global health, affecting individuals of all ages across diverse communities. While the virus has predominantly been associated with severe outcomes in adults, its impact on children has g…
View article: Oral immunization with <i>Shigella sonnei</i> WRSs2 and WRSs3 vaccine strains elicits systemic and mucosal antibodies with functional anti-microbial activity
Oral immunization with <i>Shigella sonnei</i> WRSs2 and WRSs3 vaccine strains elicits systemic and mucosal antibodies with functional anti-microbial activity Open
Shigella causes bacillary dysentery and is responsible for a high burden of disease globally. Several studies have emphasized the value of functional antibody activity to understand Shigella immunity and correlates of protection. The anti-…
View article: A Longitudinal Study of Group A Streptococcal Colonization and Pharyngitis in US Children
A Longitudinal Study of Group A Streptococcal Colonization and Pharyngitis in US Children Open
Background: Group A streptococci (GAS) are a major cause of pharyngitis in children. Recently, there were severe GAS outbreaks. The aims of this study were to assess pharyngeal colonization prevalence in healthy children, to assess differe…
View article: Towards establishing correlates of protection against shigellosis: assessing immunological endpoints across immune responses to the Shigella sonnei Generalized Modules for Membrane Antigens (GMMA) candidate vaccine (1790GAHB).
Towards establishing correlates of protection against shigellosis: assessing immunological endpoints across immune responses to the Shigella sonnei Generalized Modules for Membrane Antigens (GMMA) candidate vaccine (1790GAHB). Open
Shigella spp. are a leading bacterial cause of diarrhea. No widely licensed vaccines are available and there is no generally accepted correlate of protection. We tested a S. sonnei Generalized Modules for Membrane Antigen (GMMA)-based vacc…
View article: Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial
Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial Open
Background Influenza A (H7N9) has caused multiple disease waves with evidence of strain diversification. Optimal influenza A (H7N9) prime-boost vaccine strategies are unknown. Methods We recruited participants who had received monovalent i…
View article: Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants Open
As part of a multicenter study evaluating homologous and heterologous COVID-19 booster vaccines, we assessed the magnitude, breadth, and short-term durability of binding and pseudovirus-neutralizing antibody (PsVNA) responses following a s…
View article: Towards establishing a correlate of protection against shigellosis: assessing immunological endpoints across immune responses to the Shigella sonnei 1790GAHB GMMA investigational vaccine
Towards establishing a correlate of protection against shigellosis: assessing immunological endpoints across immune responses to the Shigella sonnei 1790GAHB GMMA investigational vaccine Open
Shigella spp. are a leading bacterial cause of diarrhea. No widely licensed vaccines are available and there is no generally accepted correlate of protection. We tested a S. sonnei GMMA-based vaccine (1790GAHB) in a phase 2b, placebo-contr…
View article: Safety and Immunogenicity of an Andes Virus DNA Vaccine by Needle-Free Injection: A Randomized, Controlled Phase 1 Study
Safety and Immunogenicity of an Andes Virus DNA Vaccine by Needle-Free Injection: A Randomized, Controlled Phase 1 Study Open
Background Andes virus (ANDV), a rodent-borne hantavirus, causes hantavirus pulmonary syndrome (HPS). The safety and immunogenicity of a novel ANDV DNA vaccine was evaluated. Methods Phase 1, double-blind, dose-escalation trial randomly as…
View article: Evaluation of a Community COVID-19 Vaccine Ambassador Train-the-Trainer Program
Evaluation of a Community COVID-19 Vaccine Ambassador Train-the-Trainer Program Open
Racially minoritized groups are more likely to experience COVID-19 vaccine hesitancy and have lower vaccination rates. As part of a multi-phase community-engaged project, we developed a train-the-trainer program in response to a needs asse…
View article: A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy Adults
A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy Adults Open
Background We evaluated the associations between baseline influenza virus–specific hemagglutination inhibition (HAI) and microneutralization (MN) titers and subsequent symptomatic influenza virus infection in a controlled human infection s…
View article: Plain language summary of Pfizer-BioNTech BNT162b2 vaccine protection against COVID-19 and its safety in participants 12- to 15-years-old
Plain language summary of Pfizer-BioNTech BNT162b2 vaccine protection against COVID-19 and its safety in participants 12- to 15-years-old Open
What is this summary about? This is a summary of an article about part of a clinical study for the BNT162b2 COVID-19 vaccine, also called the Pfizer-BioNTech vaccine. The article was published in the New England Journal of Medicine in May …
View article: 1119. Covid-19 Mab Use in High-Risk Pediatric Patients
1119. Covid-19 Mab Use in High-Risk Pediatric Patients Open
Background Effective therapeutic agents for the treatment of COVID-19 have been investigated since the onset of the pandemic. Monoclonal antibodies targeting the spike protein of SARS-CoV-2 have been developed for treatment of mild or mode…
View article: Plain Language Summary of Pfizer-BioNTech BNT162b2 COVID-19 Vaccine Safety in Participants at Least 16 Years Old and Protection Against COVID-19 in Participants at Least 12 Years Old
Plain Language Summary of Pfizer-BioNTech BNT162b2 COVID-19 Vaccine Safety in Participants at Least 16 Years Old and Protection Against COVID-19 in Participants at Least 12 Years Old Open
What is this summary about? This is a summary of an article about part of a clinical study for the BNT162b2 COVID-19 vaccine, also called the Pfizer-BioNTech vaccine. The article was published in the New England Journal of Medicine in Sept…
View article: Tocilizumab for Treatment of Children and Young Adults With Severe Acute COVID-19: Experience at a Quaternary-care Children’s Hospital
Tocilizumab for Treatment of Children and Young Adults With Severe Acute COVID-19: Experience at a Quaternary-care Children’s Hospital Open
We describe the clinical characteristics and outcomes of 16 children and young adults with severe acute COVID-19 who were treated with tocilizumab. Patients who were discharged by day 28 were more likely to be treated with tocilizumab earl…
View article: Single Site Experience of the use of Monoclonal Antibodies for the Treatment of COVID-19 in High-risk Pediatric and Young Adult Patients
Single Site Experience of the use of Monoclonal Antibodies for the Treatment of COVID-19 in High-risk Pediatric and Young Adult Patients Open
Background: Effective therapeutic agents for the treatment of COVID-19 have been investigated since the onset of the pandemic. Monoclonal antibodies targeting the spike protein of SARS-CoV-2 have been developed for the treatment of mild or…
View article: A Multi-Center, Controlled Human Infection Study of Influenza A (H1N1)pdm09 in Healthy Adults
A Multi-Center, Controlled Human Infection Study of Influenza A (H1N1)pdm09 in Healthy Adults Open
Background Influenza controlled human infection model (CHIM) studies can advance development of vaccines and therapeutics. Our objective was to evaluate the associations between baseline challenge virus-specific hemagglutination inhibition…
View article: Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months
Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months Open
BackgroundWe report updated safety, efficacy, and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) from an ongoing phase 3 trial.MethodsAdults at increased risk of SARS-CoV-2 infection were randomized (2:1), stratified by age, to receive 2 dose…
View article: Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant Open
View article: Multi-site observational maternal and infant COVID-19 vaccine study (MOMI-vax): a study protocol
Multi-site observational maternal and infant COVID-19 vaccine study (MOMI-vax): a study protocol Open